1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Drug Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Anticancer Drug Market Outlook
4.1.
Market Size & Forecast
4.1.1. By Value
4.2.
Market Share &
Forecast
4.2.1.
By Indication (Breast Cancer, Blood Cancer, Prostate
Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others)
4.2.2.
By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy,
Others)
4.2.3.
By Route of Administration (Oral, Parenteral, Others)
4.2.4.
By End User (Hospitals & Clinics, Ambulatory Care
Centers, Others)
4.2.5. By
Region
4.2.6. By Company (2023)
4.3.
Market Map
5. Asia Pacific Anticancer Drug Market Outlook
5.1.
Market Size &
Forecast
5.1.1. By Value
5.2.
Market Share &
Forecast
5.2.1. By Indication
5.2.2. By Drug
5.2.3.
By Route of
Administration
5.2.4.
By End User
5.2.5. By Country
5.3.
Asia Pacific:
Country Analysis
5.3.1. China Anticancer Drug Market Outlook
5.3.1.1.
Market Size & Forecast
5.3.1.1.1.
By Value
5.3.1.2.
Market Share & Forecast
5.3.1.2.1.
By Indication
5.3.1.2.2.
By Drug
5.3.1.2.3.
By Route of
Administration
5.3.1.2.4.
By End User
5.3.2. India Anticancer Drug Market Outlook
5.3.2.1.
Market Size & Forecast
5.3.2.1.1.
By Value
5.3.2.2.
Market Share & Forecast
5.3.2.2.1.
By Indication
5.3.2.2.2.
By Drug
5.3.2.2.3.
By Route of
Administration
5.3.2.2.4.
By End User
5.3.3. Australia Anticancer Drug Market Outlook
5.3.3.1.
Market Size & Forecast
5.3.3.1.1.
By Value
5.3.3.2.
Market Share & Forecast
5.3.3.2.1.
By Indication
5.3.3.2.2.
By Drug
5.3.3.2.3.
By Route of
Administration
5.3.3.2.4.
By End User
5.3.4. Japan Anticancer Drug Market Outlook
5.3.4.1.
Market Size & Forecast
5.3.4.1.1.
By Value
5.3.4.2.
Market Share & Forecast
5.3.4.2.1.
By Indication
5.3.4.2.2.
By Drug
5.3.4.2.3.
By Route of
Administration
5.3.4.2.4.
By End User
5.3.5. South Korea Anticancer Drug Market Outlook
5.3.5.1.
Market Size & Forecast
5.3.5.1.1.
By Value
5.3.5.2.
Market Share & Forecast
5.3.5.2.1.
By Indication
5.3.5.2.2.
By Drug
5.3.5.2.3.
By Route of
Administration
5.3.5.2.4.
By End User
6. Europe Anticancer Drug Market Outlook
6.1.
Market Size &
Forecast
6.1.1. By Value
6.2.
Market Share &
Forecast
6.2.1. By Indication
6.2.2. By Drug
6.2.3. By Route
of Administration
6.2.4. By End
User
6.2.5. By
Country
6.3.
Europe: Country
Analysis
6.3.1. France Anticancer Drug Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Indication
6.3.1.2.2.
By Drug
6.3.1.2.3.
By Route of
Administration
6.3.1.2.4.
By End User
6.3.2. Germany Anticancer Drug Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Indication
6.3.2.2.2.
By Drug
6.3.2.2.3.
By Route of
Administration
6.3.2.2.4.
By End User
6.3.3. Spain Anticancer Drug Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Indication
6.3.3.2.2.
By Drug
6.3.3.2.3.
By Route of
Administration
6.3.3.2.4.
By End User
6.3.4. Italy Anticancer Drug Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Indication
6.3.4.2.2.
By Drug
6.3.4.2.3.
By Route of
Administration
6.3.4.2.4.
By End User
6.3.5. United Kingdom Anticancer Drug Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Indication
6.3.5.2.2.
By Drug
6.3.5.2.3.
By Route of
Administration
6.3.5.2.4.
By End User
7. North America Anticancer Drug Market Outlook
7.1.
Market Size &
Forecast
7.1.1. By Value
7.2.
Market Share &
Forecast
7.2.1. By Indication
7.2.2. By Drug
7.2.3. By Route
of Administration
7.2.4. By End
User
7.2.5. By Country
7.3.
North America:
Country Analysis
7.3.1. United States Anticancer Drug Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Indication
7.3.1.2.2.
By Drug
7.3.1.2.3.
By Route of
Administration
7.3.1.2.4.
By End User
7.3.2. Mexico Anticancer Drug Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Indication
7.3.2.2.2.
By Drug
7.3.2.2.3.
By Route of
Administration
7.3.2.2.4.
By End User
7.3.3. Canada Anticancer Drug Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Indication
7.3.3.2.2.
By Drug
7.3.3.2.3.
By Route of
Administration
7.3.3.2.4.
By End User
8. South America Anticancer Drug Market Outlook
8.1.
Market Size &
Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Indication
8.2.2. By Drug
8.2.3. By Route
of Administration
8.2.4. By End
User
8.2.5. By Country
8.3.
South America:
Country Analysis
8.3.1. Brazil Anticancer Drug Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Indication
8.3.1.2.2.
By Drug
8.3.1.2.3.
By Route of Administration
8.3.1.2.4.
By End User
8.3.2. Argentina Anticancer Drug Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Indication
8.3.2.2.2.
By Drug
8.3.2.2.3.
By Route of
Administration
8.3.2.2.4.
By End User
8.3.3. Colombia Anticancer Drug Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Indication
8.3.3.2.2.
By Drug
8.3.3.2.3.
By Route of
Administration
8.3.3.2.4.
By End User
9. Middle East and Africa Anticancer Drug Market
Outlook
9.1.
Market Size &
Forecast
9.1.1. By Value
9.2.
Market Share &
Forecast
9.2.1. By Indication
9.2.2. By Drug
9.2.3. By Route
of Administration
9.2.4. By End
User
9.2.5. By Country
9.3.
MEA: Country
Analysis
9.3.1. South Africa Anticancer Drug Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Indication
9.3.1.2.2.
By Drug
9.3.1.2.3.
By Route of Administration
9.3.1.2.4.
By End User
9.3.2. Saudi Arabia Anticancer Drug Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Indication
9.3.2.2.2.
By Drug
9.3.2.2.3.
By Route of
Administration
9.3.2.2.4.
By End User
9.3.3. UAE Anticancer Drug Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Indication
9.3.3.2.2.
By Drug
9.3.3.2.3.
By Route of
Administration
9.3.3.2.4.
By End User
10.
Market Dynamics
10.1.
Drivers
10.2.
Challenges
11.
Market Trends &
Developments
11.1.
Recent Developments
11.2.
Product Launches
11.3.
Mergers &
Acquisitions
12.
Global Anticancer
Drug Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1.
Competition in the Drug
13.2.
Potential of New
Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute
Product
14.
Competitive
Landscape
14.1. F. Hoffmann-La Roche Ltd.
14.1.1.
Company Snapshot
14.1.2.
Product &
Services
14.1.3.
Financials (In case
of listed)
14.1.4.
Recent Developments
14.1.5.
SWOT Analysis
14.2. Genentech, Inc.
14.3. Novartis AG
14.4. Pfizer Inc.
14.5. Bristol-Myers Squibb Company
14.6. GlaxoSmithKline plc.
14.7. Eli Lilly and Company (India) Pvt. Ltd.
14.8. AstraZeneca plc
14.9. Sanofi S.A.
14.10.Bayer AG
15.
Strategic Recommendations
16.
About Us & Disclaimer